GSK Biologicals
US Clinical and Medical Affairs
2301 Renaissance Boulevard, RN0220
King of Prussia,
PA
USA
PA 19406
Biographical Sketch:
PROFESSIONAL EXPERIENCE
2005-present –GSK Biologicals, US Clinical and Medical Affairs
2005-2008 – Associate Director, Clinical Development (Responsible for clinical development programs and medical affairs activities for pediatric and adult vaccines)
2002-2005 – Clinical Development, Cardiovascular/Metabolism MDC
2003-2005 – Assistant Director, Clinical Development
2002-2003 – Lead Clinical Development Scientist [Avandaryl (Avandia/Amaryl FDC)]
2001-2002 - Senior Clinical Scientist, Cardiovascular and Urology Clinical Development and Product Strategy
2000-2001 – Senior Clinical Scientist, Metabolism Therapeutic Area,
1997-2000 – Clinical Research Scientist, Pulmonary/Metabolism Therapeutic Unit,
1989-1997 - Thomas Jefferson University, Philadelphia, PA
1992-1997 - Research Assistant Professor, Department of Pathology, Anatomy, and Cell Biology [Research interests: Genetic and biochemical control of mammalian craniofacial development]
1989-1992 - Postdoctoral Fellow, Department of Anatomy
PUBLICATIONS
Weston WM, et al (2009). Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults. Human Vaccines 5(12):858-866.
Blatter M, et al (2009). Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid, and three-component acellular pertussis vaccine in adults 19-64 years of age. Vaccine 27(5):765-772.
Zangwill KM, et al (2008). A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization. Pediatrics 122(6):e1179-e1185.
Weston WM and Klein NP (2008). Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years. Expert Reviews of Vaccines 7(9):1309-1320.
Black S, et al (2008) Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age. The Pediatric Infectious Disease Journal 27(4):341-346.
Bakris GL, et al (2006) Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. Journal of Hypertension. 24(10):2047-2055.
Bakris G, et al (2003) Rosiglitazone reduces urinary albumin excretion in Type 2 diabetes. Journal of Human Hypertension 17:7-12.
Haffner S, et al (2002) Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes. Circulation 106:679-684.
Nugent P, et al (2001) Identification of trisomy 16 murine embryos by fluorescence in situ hybridization. Biotechniques. 31(2):284-288.